Health Technology Assessment, green Case study cover on Heart of the Matter

Our client came to us while trying to determine whether to invest in a re-submission of their orphan drug to the Scottish Medicines Consortium (SMC). They wanted to undertake an analysis that would provide some measurement of the likelihood of success with re-submission.

Download

How Glympse Bio oversubscribed their Series B funding amidst the pandemic

View Now